Drug intelligence / Profile preview

LZ901S

Development stage: Unknown
Lead developer: Beijing Luzhu Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LZ901S is a recombinant protein vaccine candidate developed by Beijing Luzhu Biotechnology (also known as Green Bamboo Biopharmaceutical). It is specifically designed to target variants of the SARS-CoV-2 virus, the causative agent of COVID-19. The vaccine utilizes recombinant protein technology to present viral antigens, typically derived from the spike protein of specific variants, to the immune system to elicit a protective response, including the production of neutralizing antibodies and the activation of cellular immunity. As of early 2024, the candidate is in Phase 1 clinical development.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on LZ901S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ901S.

Explore the full profile